Inhibikase Therapeutics 

Yahoo Finance • 9 days ago

Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WILMINGTON, Del., April 03, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), today announced that the Company granted non-qualified stock options to purchase up to an aggregate of 685,718... Full story

Yahoo Finance • 2 months ago

Bank of America Predicts Up to 240% Jump for These 2 ‘Strong Buy’ Stocks

The stock market has been treading water so far this year, with the S&P 500 up roughly 1% while the Nasdaq has slipped 1.5%. Tech stocks have struggled to regain last year’s momentum as investors reassess the durability of AI-driven spendi... Full story

Yahoo Finance • 5 months ago

Inhibikase Therapeutics sells 68.97M shares and pre-funded warrants at $1.45/share

Clinical-stage pharmaceutical company Inhibikase Therapeutics (IKT [https://seekingalpha.com/symbol/IKT]) announced the pricing [https://seekingalpha.com/pr/20316733-inhibikase-therapeutics-announces-pricing-of-100-million-public-offering-... Full story

Yahoo Finance • 5 months ago

Inhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants

WILMINGTON, Del., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing therapeutics to modify the course of pulmonary arterial hyper... Full story

Yahoo Finance • 5 months ago

Inhibikase Therapeutics announces proposed public offering and pre-funded warrants

* Inhibikase Therapeutics (NASDAQ:IKT [https://seekingalpha.com/symbol/IKT]) announced [https://seekingalpha.com/pr/20316495-inhibikase-therapeutics-announces-proposed-public-offering-of-common-stock-and-pre-funded] on Thursday that it h... Full story

Yahoo Finance • 5 months ago

Inhibikase Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

BOSTON and ATLANTA, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing therapeutics to modify the course of pulmonary arterial hyp... Full story

Yahoo Finance • 5 months ago

Inhibikase Therapeutics Advancing IKT-001 to Global Phase 3 Study in Pulmonary Arterial Hypertension

Phase 3 Study initiating in First Quarter of 2026 Single Pivotal Study Accelerates Potential FDA Approval Timeline by Approximately 3 Years BOSTON and ATLANTA, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq:... Full story

Yahoo Finance • 5 months ago

Inhibikase Therapeutics GAAP EPS of -$0.13

* Inhibikase Therapeutics press release [https://seekingalpha.com/pr/20308610-inhibikase-therapeutics-announces-third-quarter-2025-financial-results-and-highlights-recent] (IKT [https://seekingalpha.com/symbol/IKT]): Q3 GAAP EPS of -$0.1... Full story

Yahoo Finance • 5 months ago

Inhibikase Therapeutics Announces Third Quarter 2025 Financial Results and Highlights Recent Activity

BOSTON and ATLANTA, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseas... Full story

Yahoo Finance • 8 months ago

These stocks are moving in today's pre-market session

As the US market prepares to open on Monday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses. [premarket] PRE-MARKET GAINERS TICKER CHANGE COMMENT V... Full story

Yahoo Finance • 8 months ago

Inhibikase Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Activity

BOSTON and ATLANTA, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseas... Full story

Yahoo Finance • 9 months ago

Inhibikase Therapeutics shareholders elect directors and approve equity plan changes

Inhibikase Therapeutics, Inc. (NASDAQ:IKT), a pharmaceutical company currently trading near $1.95 and showing a strong 17.47% gain over the past week, held its 2025 Annual Meeting of Stockholders on Friday. According to a statement based o... Full story

Yahoo Finance • 10 months ago

Ludwig Enterprises appoints Garth Lees-Rolfe as independent director

Ludwig Enterprises, Inc. (OTC:LUDG) announced the appointment of Garth Lees-Rolfe as an independent director, effective Monday. The decision was made by the company’s board of directors and was disclosed in a press release statement based... Full story

Yahoo Finance • 10 months ago

Inhibikase Therapeutics files $300M mixed securities shelf

* Inhibikase Therapeutics (NASDAQ:IKT [https://seekingalpha.com/symbol/IKT]) filed $300M mixed securities shelf. * Filing [https://seekingalpha.com/filing/10116244] MORE ON INHIBIKASE THERAPEUTICS * Inhibikase Therapeutics: A Hold... Full story

Yahoo Finance • last year

Inhibikase Therapeutics Announces 2024 Financial Results and Highlights Recent Activity

BOSTON, March 27, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company innovating small molecule kinase inhibitor therapeutics to treat pulmonary arteri... Full story

Yahoo Finance • 2 years ago

Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Period Activity

BOSTON and ATLANTA, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of P... Full story

Yahoo Finance • 2 years ago

Correcting & Replacing -- Inhibikase Therapeutics to Report Third Quarter Financial Results on November 14, 2023

This release corrects and replaces the headline in the release that was disseminated on November 7, 2023. The reason for this correction is to fix the title which previously stated, "second quarter" rather than "third quarter." BOSTON and... Full story

Yahoo Finance • 2 years ago

Inhibikase Therapeutics to Report Second Quarter Financial Results on November 14, 2023

BOSTON and ATLANTA, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course... Full story

Yahoo Finance • 2 years ago

Inhibikase Therapeutics Highlights Unblinded Functional Analysis from the 201 Trial of Risvodetinib in Untreated Parkinson’s Disease and Provides Update on Ongoing Enrollment

BOSTON and ATLANTA, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of P... Full story

Yahoo Finance • 3 years ago

Inhibikase Therapeutics Receives FDA Orphan Drug Designation for Risvodetinib for the Treatment of Multiple System Atrophy

BOSTON and ATLANTA, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of P... Full story